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MicroRNA Levels as Prognostic Markers
for the Differentiation Potential of Human Mesenchymal
Stromal Cell Donors
Nicole Georgi,1 Hanna Taipaleenmaki,2 Christian C. Raiss,3 Nathalie Groen,4
Karolina Janaeczek Portalska,4 Clemens van Blitterswijk,4 Jan de Boer,4
Janine N. Post,1 Andre J. van Wijnen,5 and Marcel Karperien1
The ability of human mesenchymal stromal/stem cells (hMSCs) to differentiate into various mesenchymal cell
lineages makes them a promising cell source for the use in tissue repair strategies. Since the differentiation
potential of hMSCs differs between donors, it is necessary to establish biomarkers for the identification of
donors with high differentiation potential. In this study, we show that microRNA (miRNA) expression levels
are effective for distinguishing donors with high differentiation potential from low differentiation potential.
Twenty hMSC donors were initially tested for marker expression and differentiation potential. In particular, the
chondrogenic differentiation potential was evaluated on the basis of histological matrix formation, mRNA
expression levels of chondrogenic marker genes, and quantitative glycosaminoglycan deposition. Three donors
out of twenty were identified as donors with high chondrogenic potential, whereas nine showed moderate and
eight showed low chondrogenic potential. Expression profiles of miRNAs involved in chondrogenesis and
cartilage homeostasis were used for the distinction between high-performance hMSCs and low-performance
hMSCs. Global mRNA expression profiles of the donors before the onset of chondrogenic differentiation
revealed minor differences in gene expression between low and high chondrogenic performers. However,
analysis of miRNA expression during a 7-day differentiation period identified miR-210 and miR-630 as positive
regulators of chondrogenesis. In contrast, miR-181 and miR-34a, which are negative regulators of chon-
drogenesis, were upregulated during differentiation in low-performing donors. In conclusion, profiling of hMSC
donors for a specific panel of miRNAs may have a prognostic value for selecting donors with high differen-
tiation potential to improve hMSC-based strategies for tissue regeneration.
Introduction
Human mesenchymal stromal/stem cells (hMSCs) area multipotent cell source that can be easily harvested
from various locations of the body, including bone marrow,
periosteum, synovium, synovial fluid, adipose tissue, buccal fat
pad, infrapatellar fat pad, and osteoarthritic cartilage [1–6]. The
ability of hMSCs to differentiate into mesenchymal tissues, such
as the bone and cartilage, and their potential as trophic media-
tors render them particularly suitable for tissue engineering [7].
Unfortunately, large interdonor variation of the differen-
tiation potential is a general complication for the practical
implementation of hMSC-based tissue engineering ap-
proaches [8,9]. Donor age, method or location of harvest,
culture conditions, and culture time are known to affect the
differentiation potential of hMSCs [10–16]. Jansen et al.
suggested that distinctions in mRNA gene expression pro-
files might be predictive for the differentiation potential
[17]. However, specific biomarkers indicative for the dif-
ferentiation potential of undifferentiated hMSCs remain to
be defined.
Studies on the genetic and epigenetic mechanisms that
control the differentiation potential of hMSCs have focused
on characterizing variation in both mRNA and miRNA
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expression levels [18–21]. MicroRNAs (miRNAs) control
cell fate by negatively regulating protein accumulation through
effects on the stability and/or translation of mRNAs for tran-
scription factors and their phenotypic target genes. Hence,
miRNAs are very relevant molecular candidates for mapping
the proliferation and differentiation potential of hMSCs.
In this study, we tested a series of bone marrow-derived
hMSCs from a cohort of donors for their potential to un-
dergo chondrogenesis. This cohort has previously been
characterized in great detail with respect to the osteogenic,
adipogenic, endothelial cell differentiation potential and CD
marker expression [22,23] and meets the criteria proposed
by the Mesenchymal and Tissue Stem Cell Committee of the
International Society for Cellular Therapy [24]. Similar to
differentiation into other cell types, the chondrogenic po-
tential varied significantly between donors.
The biological properties of these hMSCs were correlated
with global mRNA expression profiles using microarray
assays and quantitative polymerase chain reaction (qPCR)
expression analysis of a select panel of miRNAs. To permit
identification of miRNAs with a predictive value for chon-
drogenic differentiation, we examined miRNA expression
both before the onset of differentiation and after the in-
duction of chondrogenic differentiation at day 7 in pellet
culture. We found that miRNA profiling of hMSC donors
and patients may have a prognostic value in regenerative
medicine by permitting identification of hMSCs that are
most effective in supporting differentiation.
Materials and Methods
Cell expansion and differentiation
The use of human bone marrow aspirates was approved
by the local medical ethics committee with written informed
consent by the donors [25]. Aspirates were retrieved during
total hip replacement surgery from the acetabulum or iliac
crest (average age: 52 years, 25% male and 75% female).
Aspirates were resuspended using a 20G needle and plated
at a density of 0.5 million mononucleated cells/cm2. MSCs
were selected by plastic adherence in proliferation media
[alpha modified minimum essential medium, 10% fetal bo-
vine serum (Lonza), 0.2 mM ascorbic acid, 2 mM l-gluta-
mine, 100 U/mL penicillin, 100 mg/mL streptomycin, and
1 ng/mL of basic fibroblast growth factor (Instruchemie)].
hMSCs were expanded up to passage 2 and used in passage
3 to test their differentiation potential. The determination of
cell surface marker expression (CD105, CD11b, CD19,
CD45, HLA-DR, CD90, CD73, CD34), osteogenic poten-
tial, adipogenic potential, and endothelial induction of the
used hMSC donors is described elsewhere [22,23].
Chondrogenic differentiation
To induce chondrogenic differentiation, 250,000 hMSCs
were seeded in round-bottom 96-well plates [26] at passage
2. Pellets were formed by centrifugation (500 rcf, 5 min) and
maintained in chondrogenic differentiation media. This
medium consists of Dulbecco’s Modified Eagle’s Medium
supplemented with 40 mg/mL of proline, 50 mg/mL ITS-
premix, 50 mg/mL of ascorbic acid, 100 mg/mL of sodium
pyruvate, 100 U penicillin/mL, 100 mg/mL streptomycin,
10 ng/mL of transforming growth factor-b, and 10-7 M of
dexamethasone. Cells were cultured for 4 weeks for deter-
mination of glycosaminoglycan (GAG) deposition (quanti-
tative and qualitative) and qPCR of chondrogenic markers
and 1 week for the qPCR analysis of chondrogenesis-related
miRNAs, as previously described [26]. Media were changed
twice a week.
Histology: Alcian Blue staining
After 4 weeks, chondrogenic culture pellets were fixed with
10% buffered formalin for 15 min, dehydrated, and embedded
in paraffin using routine procedures. Sections of 5 mm were
cut and stained for sulfated GAGs with Alcian Blue (0.5%, in
H2O, pH = 1 adjusted with HCl, 30 min) combined with
counterstaining of Nuclear Fast Red (0.1% in 5% aluminum
sulfate, 5 min). Scoring of histology was performed by three
independent blinded observers according to the intensity of
Alcian Blue staining and morphology of the formed pellets.
mRNA isolation and qPCR
After 4 weeks of chondrogenic culture, total RNA was
isolated from pellet cultures with the NucleoSpin RNA II
Kit (Bioke) and 1 mg of RNA was reverse-transcribed into
cDNA using the iScript cDNA Synthesis Kit (Bio-Rad)
according to the manufacturer’s protocols. The primers for
qPCR are listed in Table 1. mRNA expression levels were
normalized with GAPDH and B2M as housekeeping genes.
All reagents were purchased from Invitrogen, unless
otherwise stated. Common chemicals were purchased from
Sigma-Aldrich.
Microarray expression profiling
Gene expression profiling of 20 hMSC donors was carried
out using the Affymetrix microarray platform. RNA isolated
at passage 2 before the initiation of the chondrogenic dif-
ferentiation was hybridized to the Human Genome U133A
2.0 Array (Affymetrix) and scanned with a GeneChip G3000
scanner (Affymetrix). Measurements were normalized for







ACAN 5¢ AGGCAGCGTGATCCTTACC 3¢ 136
5¢ GGCCTCTCCAGTCTCATTCTC 3¢
COL1A1 5¢ GTCACCCACCGACCAAGAAACC 3¢ 121
5¢ AAGTCCAGGCTGTCCAGGGATG 3¢
COL2A1 5¢ CGTCCAGATGACCTTCCTACG 3¢ 122
5¢ TGAGCAGGGCCTTCTTGAG 3¢
COL10A1 5¢ GCAACTAAGGGCCTCAATGG 3¢ 129
5¢ CTCAGGCATGACTGCTTGAC 3¢
SOX9 5¢ TGGGCAAGCTCTGGAGACTTC 3¢ 98
5¢ ATCCGGGTGGTCCTTCTTGTG 3¢
FRZB 5¢ ACGGGACACTGTCAACCTCT 3¢ 155
5¢ CGAGTCGATCCTTCCACTTC 3¢
GAPDH 5¢ CGCTCTCTGCTCCTCCTGTT 3¢ 101
5¢ CCATGGTGTCTGAGCGATGT 3¢
B2M 5¢ GACTTGTCTTTCAGCAAGGA 3¢ 106
5¢ ACAAAGTCACATGGTTCACA 3¢




















































technical effects related to efficiency of hybridization and
amplification of nucleic acids, as well as the physical loca-
tion on the array. Data processing and statistical testing were
performed using R and Bioconductor statistical software
(www.bioconductor.org). Analysis to determine differential
gene expression was performed using a linear modeling ap-
proach with empirical Bayesian methods, as implemented in
the Limma package [27] and described in more detail in
Mentink et al. [22]. Raw and normalized data have been
deposited in the Gene Expression Omnibus database (http://
ncbi.nlm.nih.gov/geo/, GSE39540). Search Tool for the Re-
trieval of Interacting Genes/Proteins (STRING) was used
to investigate the predicted gene–gene interaction network
[28,29]. Clusters were formed using Markov clustering al-
gorithms. Changes in upstream regulators and biofunctions
were visualized using Ingenuity Pathway Analysis software
(IPA; Ingenuity Systems).
In this study, the described data set was previously used by
Portalska et al. and Mentink et al. [22,23]. We reanalyzed this
data set after the formation of two groups: good and low
chondrogenic performing hMSC donors. To correlate donor
variation with chondrogenic differentiation ability, we scored
different donor-derived hMSCs based on their histological
pellet culture appearance, GAG deposition, and expression of
mRNA markers of chondrogenesis after 28 days of differ-
entiation. Subsequently, a list of genes ranked on fold change
between the highest and lowest chondrogenically performing
donors was generated using the approach described above.
miRNA isolation and qPCR
Small RNAs were isolated from monolayer hMSC cul-
tures at passage 2 and from pellet cultures at day 7 after
initiation of chondrogenic differentiation with the AllPrep
DNA/RNA/Protein Mini Kit in combination with the
RNeasy MinElute Cleanup Kit according to the manu-
facturer’s protocol (Qiagen). Nucleic acid concentrations
were measured with the NanoDrop 2000. The small RNA
fraction cDNA was prepared using the RevertAid H Minus
First Strand cDNA Synthesis Kit (Fermentas). SYBR (N¢,N¢-
dimethyl-N-[4-[(E)-(3-methyl-1,3-benzothiazol-2-ylidene)
methyl]-1-phenylquinolin-1-ium-2-yl]-N-propylpropane-
1,3-diamine) green mRNA Primer sequences are listed in
Table 2. The QuantiMir RT Kit (Systems Biosciences) was
used according to the manufacturer’s instruction to convert
small RNAs into cDNA. Expression levels were analyzed by
quantitative reverse transcription–polymerase chain reaction
(qRT-PCR; SYBR Green supermix and iCycler IQ detection
system; Bio-Rad) using conventional protocols [30]. The
relative expressions were calculated by the DCT method
normalized to U6 expression.
The qRT-PCR data were analyzed using one-way analysis
of variance with Tukey as the post hoc test (different sized
groups) in SPSS. Significance levels of P £ 0.05 are indi-
cated with an asterisk (*).
Results
Limited chondrogenic potential of hMSC donors
hMSCs from a cohort of 20 donors were tested previously for
their endothelial, adipogenic, osteogenic, and chondrogenic
differentiation potential. All donor hMSCs expressed the an-
ticipated CD marker profile of hMSCs [22,23]. We compared
the chondrogenic potential in depth based on histological ap-
pearance, GAG deposition, and chondrogenic mRNA expres-
sion. This analysis revealed that only three donors show
substantial chondrogenesis after 28 days of pellet culture.
Another nine donors show moderate levels of chondrogenesis
and eight donors have only a low potential to undergo chon-
drogenesis (Supplementary Fig. S1; Supplementary Data are
available online at www.liebertpub.com/scd). Alcian Blue
stain for the GAG of two representative donors of each group
revealed that intensity of staining is decreasing from donors
with high chondrogenic potential to donors with low chon-
drogenic potential. Reduction in GAGs is paralleled by limited
abundance of encapsulated chondrocyte units (ie, reduced
chondron formation), increased fibrous cartilage formation,
and a higher cell to matrix ratio (Fig. 1A).
Gene expression levels of the chondrogenic genes ACAN
and COL2A1 were significantly upregulated in donors with
high chondrogenic potential. The chondrogenic transcription
factors SOX9 and FRZB, a recently identified marker for
articular cartilage, were nonsignificantly higher expressed in
good chondrogenic performers. COL10A1, a marker for
cartilage hypertrophy, was significantly higher expressed in
high-performing donors. COL1A1, a dedifferentiation mar-
ker, exhibits limited variation in expression between the
different groups (Fig. 1B). Donors with high chondrogenic
potential show distinct quantitative GAG levels from mod-
erate to low performers (Fig. 1C). Histologically assessed
GAG levels did not distinguish moderate from low-performing
donors (Fig. 1C). Thus, high-performing chondrogenic hMSCs
are distinct from biologically low-performing hMSCs by
both histochemical and molecular criteria.
Microarray-based mRNA expression profiling shows
limited distinctions between hMSCs with different
chondrogenic potential
Analysis of global gene expression levels between all 20
donors revealed minor mRNA expression differences between
the high-, moderate-, and low-performing donors. To improve
Table 2. Primers Used for the Quantitative










































































FIG. 1. Comparison of 20 human mesenchymal stromal/stem cell (MSC) donors for their chondrogenic potential based on
histological appearance, mRNA expression, and glycosaminoglycan (GAG) deposition. (A) Alcian Blue stain for GAG of
two representative donors of each group: high chondrogenic potential (a, b) to donors with moderate (c, d) and low
chondrogenic potential (e, f). (B) Gene expression levels of the chondrogenic genes ACAN, COL2A1, and COL10A1 were
assessed with quantitative polymerase chain reaction analysis using mRNAs. Data represent the three donors in the high-
performing group, nine donors in the moderate group, and eight donors in the low-performing group – standard deviation
(SD) (*P £ 0.05). (C) GAG levels as overview for all 20 donors: donors with high chondrogenic potential demonstrate
distinct quantitative GAG levels compared to moderate and low performers. The average measure of three different pellets





















































detection of molecular differences, we compared mRNA levels
upon biological stratification of the donors into two groups with
either high or low chondrogenic potential (n = 3 in each case)
using the extremes at both ends of the spectrum of chondrogenic
differentiation based on histology, quantitative GAG assess-
ment, and gene expression analysis. Statistical evaluation of
these highly distinct groups increased the number of signifi-
cantly differentially expressed genes, but differences in global
gene expression levels were small (Supplementary Table S1).
STRING network analysis of genes with a minimal 1.6-fold
(log ratio 0.5) upregulation in donors with high chondrogenic
potential compared to low-performing donors demonstrated
changes in regulatory networks associated with transcriptional
control and signal transduction. One major network includes
the basic helix-loop-helix family member E40 (BHLHE40),
which is a transcription factor modulating chondrogenesis
[31]. Furthermore, several other gene regulatory factors were
identified, such as the nuclear receptor group 4A2 (NR4A2,
also known as NURR1) as well as the basic leucine zipper
(bZIP) proteins ATF3, MAFB, FOSB, and FOS. Each of
these regulators has been linked to signal transduction, cell
proliferation, and differentiation [32] (Fig. 2A).
Network analysis of genes with a minimal 1.4-fold
downregulation in donors with low chondrogenic potential
compared to donors with high chondrogenic potential re-
vealed major networks associated with extracellular matrix
proteins, such as ACAN, COL4A1, TIMP3, and EFEMP1, as
well as a network of signaling proteins, JAG1, dickkopf-
related protein 1 (DKK1), and tumor necrosis factor receptor
superfamily member 11B (TNFRSF11B, also known as os-
teoprotegerin/OPG) (Fig. 2B).
Ingenuity pathway analysis revealed that the 10 most
differentially regulated cellular functions between the three
high- and low-performing donors were linked to development
as well as cell growth and survival (Fig. 2C). Transforming
growth factor (TGF)-b1 was identified as a major upstream
contributor to the differences in gene expression between
donors with high and low chondrogenic potential (Fig. 2D).
FIG. 2. Microarray mRNA analysis as a result of the comparison of three high-performing chondrogenic donors versus
low-performing chondrogenic donors. (A) Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) network
analysis of genes with a minimal 1.4-fold upregulation in donors with high chondrogenic potential compared to inefficient
performing donors. (B) STRING network analysis of genes with a minimal 1.4-fold downregulation in donors with low
chondrogenic potential compared to donors with high chondrogenic potential. The number of connecting lines indicates the
reported evidence of connection between displayed proteins. (C) Ingenuity pathway analysis of the top 10 differentially
regulated cellular functions between the three high- and low-performing donors. (D) Transforming growth factor-b1 was
identified as a major upstream contributor to the differentially regulated genes between donors with high and low chon-
drogenic potential. Color images available online at www.liebertpub.com/scd




















































Differential expression of miRNAs between groups
with distinct chondrogenic potential
Since mRNA expression changes did not reveal clear
markers of chondrogenic potential, we investigated the po-
tential of miRNA expression as markers of chondrogenic
potential in hMSCs. The expression of previously identified
miRNAs known to be involved in chondrogenesis was
evaluated before onset of chondrogenic differentiation and
after 7 days in a three-dimensional cell mass under chon-
drogenic conditions (pellet culture). miRNA levels of the
same three donors with high chondrogenic potential (n = 3)
were compared with the same three donors with lowest
chondrogenic potential (n = 3).
Two miRNAs, which are known to negatively influence
osteoblast and chondrocyte differentiation (miR-30b and
-221), display a higher expression in high-performing do-
nors before the onset of chondrogenesis (fold upregulation
high-performing donor/low-performing donor: miR-30b:
1.63, miR-221: 1.83). Both miRNAs were strongly down-
regulated during chondrogenic differentiation (fold down-
regulation day 0/day 7: miR-30b: 4.10, miR-221: 7.86).
However, these same miRNAs were not or weakly down-
regulated in low-performing chondrogenic donors, marked
by a lower fold change between day 0 and 7 after induction
of chondrogenic differentiation (fold downregulation day 0/
day 7: miR-30b: 0.94, miR-221: 2.72).
One set of miRNAs (miR-34a, -23b, -26, -181) was more
highly expressed in donors with high chondrogenic potential
before the onset of chondrogenesis (fold difference between
high- vs. low-performing donors: miR-34a: 2.46-fold, miR-
23b: 1.25-fold, miR-26: 1.54-fold, miR-181: 1.15-fold).
These miRNAs were all downregulated during differentia-
tion (fold downregulation day 0/day 7: miR-34a: 3.70-fold,
miR-23b: 1.67-fold, miR-26: 1.20-fold, miR-181: 1.10-fold).
Remarkably, while their expression in poor performing do-
nors was lower compared to good performing donors before
the onset of chondrogenic differentiation, their expression
was upregulated during differentiation (fold upregulation day
0/day 7: miR-34a: 1.90-fold, miR-23b: 1.30-fold, miR-26:
1.60-fold, miR-181: 1.39-fold). Notably, miR-34a and miR-
23b are known to negatively influence cartilage homeostasis
and/or chondrogenic differentiation.
In contrast, expression of miR-630, a positive regulator of
chondrogenesis, and miR-210, a marker of the hypoxic cell
response, is upregulated during chondrogenesis (fold upre-
gulation day 0/day 7: good donors miR-630: 1.99, miR-210:
14.14; low donors: miR-630: 3.52, miR-210: 21.93). Re-
markably, their upregulation was even more pronounced in
the poor performing donors, demonstrating discordance.
Other regulators of chondrogenesis (miR-140,-145, and let-7e)
display only minor differences between the different groups
(Fig. 3; Table 3).
Discussion
By the comparison of the chondrogenic differentiation
potential of previously well-characterized hMSCs from a
cohort of human donors (n = 20), it was shown that only
15% of these donors provide hMSCs with the natural ca-
pability to undergo efficient chondrogenic differentiation ex
vivo [22,23], while chondrogenic performance was moder-
ate (45%) or even poor in the remaining donors (40%).
Good chondrogenic differentiation potential was mainly
marked by increased GAG deposition, better histological
cartilage formation, including increased formation of matrix
encapsulated chondrocytes (ie, chondron formation), limited
fibrous cartilage formation, as well as the significantly
higher mRNA expression of ACAN and COL2A1.
The main focus of our study was, therefore, to define
molecular differences that predict high differentiation hMSC
donors at the start of the differentiation experiment. We would
like to emphasize that this pool of MSCs was isolated from
bone marrow biopsies by virtue of plastic adherence using
protocols routinely applied for isolation and culture expansion
of bone marrow MSCs for clinical practice [33]. Our MSCs
were not clonally selected and they are likely to present a
heterogenic cell population as previously noted [24].
Previous studies have mainly focused on the osteogenic
differentiation of hMSC donors. In these studies, only dif-
ferences in differentiation potential were noticed and no
scoring was done. Differences in performances were shown
to be independent of donor age, gender, and source of iso-
lation [9,22,34]. As demonstrated by Mentink et al. [22],
high osteogenic potential of a particular donor does not
imply that this donor also exhibits high chondrogenic, adi-
pogenic, or endothelial differentiation potential. We, there-
fore, want to emphasize that prognostic markers have to be
identified for each differentiation lineage separately.
In our study, we tested if donors with high chondrogenic
potential could be identified in a pool of donors based on
their global gene expression profile determined by Affymetrix
FIG. 3. MicroRNA (miRNA) level regulation of high-
performing vs low-performing donors. Expression of miRNAs
known to be involved in chondrogenesis was evaluated before
chondrogenesis and at day 7 of chondrogenic pellet culture.
miRNA levels of donors with high chondrogenic potential
(n = 3) were compared with donors with low chondrogenic po-
tential (n = 3). miR-30, -221, 34a, -23b, -26, -181 display a higher
expression in high-performing donors before the onset of
chondrogenesis and were strongly downregulated during chon-
drogenic differentiation. miR-630 and miR-210 are upregulated
during chondrogenesis. Negative regulators of chondrogenesis
(miR-145 and let-7e) are slightly downregulated during the dif-
ferentiation process in high- and low-performing donors. Data
represent the mean of three independent hMSC donors. Color
images available online at www.liebertpub.com/scd




















































microarray analysis before the onset of differentiation. Groups
with high and low chondrogenic differentiation potential were
separated with a maximum 1.6-log ratio in transcript ex-
pression levels (Supplementary Table S1).
Donors with low chondrogenic potential mainly exhibited
higher expression of matrix-associated proteins. Donors
with high chondrogenic potential showed increased expression
of mRNAs involved in transcriptional processes, although
overall differences were small. Two regulatory networks that
differ between the donor groups with high and low chondro-
genic potential are centered around the BHLHE40, as a
transcriptional factor modulating chondrogenesis [31], and
the transcription factors FOS, FOSB, and ATF3, which have
general roles in signal transduction, cell proliferation, and
differentiation [35] (Fig. 2A). FOS and ATF members are
leucine zipper proteins that dimerize with the JUN family and,
thereby, form a large number of AP-1-related transcription
factor complexes. The activation of AP-1 is linked to termi-
nal chondrocyte differentiation and cartilage homeostasis by
modulating MMP13 expression [36]. Modulation of this
transcription factor network may therefore have impact on the
chondrogenic performance of hMSCs. Hence, subtle differ-
ences in the expression of transcription factors may contribute
to distinctions in the chondrogenic potential of hMSCs.
Our studies suggested that genes, which differ between
donors with high or low chondrogenic potential, are linked
to TGFb1 as a principal upstream regulator. TGFb signaling
supports embryonic development and cartilaginous matrix
formation [37]. It is plausible that differences in TGFb
responsiveness of hMSC donors might lead to distinct
chondrogenic performance of hMSCs. Indeed, exogenous
supplementation of TGFb is a main driver of chondrogenic
differentiation in hMSC pellet cultures [38]. In addition,
TGFb is a key upstream regulator of AP-1 activity through
its downstream effectors SMAD2 and SMAD3 [39]. Thus,
differences in the TGFb/SMAD/AP1 regulatory axis could
account, in part, for differences in the chondrogenic ability
of hMSCs from different donors.
We next extended our analysis by analysis of a selected
panel of miRNAs previously implemented in chondrogenic
differentiation, including miR-210, miR-630, and miR-140
[40–43]. We confirmed positive regulation of miR-210 and
miR-630 within 7 days after chondrogenic induction, with
miR-630 being slightly higher expressed in good donors.
Bakhshandeh et al. showed that miR-630 is part of a chon-
drogenic miRNA signature [43]. Among the pathways pre-
dicted to be targeted by miR-630 are erbB signaling, gap-
junction communication, MAP-Kinase signaling, and TGFb
signaling. Both MAP-Kinase/Erk signaling and TGFb sig-
naling are mediators of early stages of chondrogenic dif-
ferentiation [44,45].
We find that miR-181 and miR-34a, which are negative
regulators of chondrogenesis, were upregulated during dif-
ferentiation in low-performing donors. Of these two, miR-34a
perturbs cartilage homeostasis by inducing apoptosis, cell
cycle arrest, and senescence while targeting for E2F3, cyclin
E2, CDK6, and others [46,47], but is otherwise unremarkable.
However, similar to one of the predicted functions for miR-
Table 3. Investigated MicroRNAs and Their Reported Function
miRNA Reported function References Observed regulation
miR-30b Negative regulation of osteoblast differentiation [48] Higher expressed in high performers at day 0
miR-221 Negative regulation of chondrocyte
differentiation
[49,50] Higher expressed in high performers at day 0;
downregulated during differentiation in high
performers; no regulation in low performers
miR-34a Regulates osteoarthritis pathogenesis [46] Higher expressed in high performers at day 0;
upregulation in low performers during
chondrogenesis
miR-23b Potentially upregulated in osteoarthritis (OA);
negative regulation of TGFb and BMP
signaling
[51,52] Higher in high performers at day 0; upregulation
in low performers during chondrogenesis
miR-26 Mediates cholesterol metabolism; hypoxic
upregulation
[53,54] Higher expressed in high performers at day 0;
upregulation in low performers during
chondrogenesis
miR-181 Regulation of TGFb signaling in chondrocytes;
downregulation during chondrogenesis;
hypoxic upregulation
[43,54,55] Higher expressed in high performers at day 0;
upregulation in low performers during
chondrogenesis
miR-210 Upregulation during chondrogenesis cell
survival of MSC hypoxic upregulation
[20,50,54] Upregulation in both donor groups during
chondrogenesis
miR-630 Activation of TGFb signaling in chondrocytes [43] Upregulation during differentiation; higher
upregulation in good responders
miR-140 Positive regulation of chondrogenesis; negative
regulation of histone deacetylase 4 (HDAC4);
regulation of OA pathogenesis;
and endochondral bone formation
[40–42] Higher expressed in high performers; decreased
during chondrogenesis
miR-145 Negatively regulates chondrogenesis
by targeting SOX9; downregulation
during chondrogenesis
[50,55,56] Higher expressed in high performers; decreased
during chondrogenesis
Let-7e Downregulation during chondrogenesis
self-renewal of stem cells
[50,57] Higher expressed in low performers;
downregulation during chondrogenesis
TGFb, transforming growth factor-beta; MSC, mesenchymal stromal/stem cell; BMP, bone morphogenetic protein.




















































630, miR-181 acts as a negative regulator of the TGFb
pathway [43]. Thus, our current findings converge on a hy-
pothetical molecular model, in which miR-630, miR-181, as
well as the TGFb/SMAD/AP-1 regulatory axis may form a
tightly connected network that modulates and predicts the
chondrogenic potential of hMSCs from different donors.
In conclusion, our findings indicate that a panel of miRNAs
encompassing miR-210, miR-630, miR-181, and miR-34a can
be informative for prognostically separating high-performing
hMSCs from low-performing hMSCs. Our data suggest that a
short preclinical differentiation period of 7 days suffices to
provide insight into the chondrogenic potential of different
hMSCs based on miRNA expression profiling. Furthermore,
modulation of TGFb responsiveness appears to be a common
mechanistic denominator in both the observed differences in
mRNA expression profiles and the differences in miRNA
expression between biologically distinct hMSCs from differ-
ent donors. We anticipate that experimental and therapeutic
manipulation of TGFb-dependent miRNA/transcription factor
networks may be useful for enhancing the chondrogenic po-
tential of hMSCs and minimizing the biological differences
among diverse patients who will undergo autologous tissue
regeneration using hMSCs.
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